Cantor Fitzgerald upgrades Rezolute as FDA signals ersodetug congenital hyperinsulinism data is sufficient for a filing. Read more here.
Rezolute (NASDAQ: RZLT) shares surged after the FDA recommended a pre-BLA meeting for its congenital hyperinsulinism drug, ersodetug.
Rezolute (RZLT) said Monday that the US Food and Drug Administration has recommended a meeting befor
Detailed price information for Protalix Biotherapeutics (PLX-A) from The Globe and Mail including charting and trades.
Rezolute (NASDAQ:RZLT) said the FDA is continuing its review of additional Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism after the study failed to meet its primary endpoint, leaving the potential regulatory path unresolved and without a specific timeline for agency feedback. Key Investor TakeawaysThe FDA review remains ongoing as the agency evaluates whether there is a potential regulatory path forward for ersodetug in congenital hyperinsulinism.
This is the newest page. Registered accounts read further back.